Nuovi agenti immunosoppressori nel trapianto

Translated title of the contribution: New immunosuppressive agents in renal transplantation

C. Ponticelli, G. Montagnino

Research output: Contribution to journalArticle

Abstract

Among the more recent immunosuppressive agents, Sirolimus and monoclonal antibodies directed against the IL-2 receptor are the most promising. Sirolimus inhibits the G1-S phase of the cell cycle, at a later stage than calcineurin inhibitors, which interfere with the G0-G1 phase. Clinical studies have demonstrated the efficacy of Sirolimus in reducing the risk of rejection when combined with CsA and steroids. Sirolimus also proved to be effective as an alternative to CsA. The monoclonal antibodies directed against the IL-2 receptor significantly reduce the risk of acute rejection without side-effects. Other immunosuppressive agents are still being assessed in phase I-H clinical studies. FTY 720 may induce selective apoptosis of lymphocytes reacting against the donor's alloantigens. Antisense oligonucleotides interfere with adhesion molecules, while the monoclonal antibodies CTLA4-Ig and 5C-8 interfere with the co-stimulatory signals between the antigen presenting cell and the lymphocyte. An ever increasing number of new immunosuppressive agents is becoming available. The difficult task of the clinician is to find the right equilibrium in dosing and associating these new drugs in order to maximize the therapeutic effect of immunosuppressive treatment.

Original languageItalian
Pages (from-to)180-185
Number of pages6
JournalGiornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
Volume16
Issue number2
Publication statusPublished - 1999

Fingerprint

Sirolimus
Immunosuppressive Agents
Kidney Transplantation
Interleukin-2 Receptors
Monoclonal Antibodies
G1 Phase
Lymphocytes
Cell Cycle Resting Phase
Isoantigens
Antisense Oligonucleotides
Therapeutic Uses
Antigen-Presenting Cells
S Phase
Cell Cycle
Steroids
Apoptosis
Pharmaceutical Preparations
Clinical Studies
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

Nuovi agenti immunosoppressori nel trapianto. / Ponticelli, C.; Montagnino, G.

In: Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia, Vol. 16, No. 2, 1999, p. 180-185.

Research output: Contribution to journalArticle

@article{98b0390cd0414ca194a33aef286a3b33,
title = "Nuovi agenti immunosoppressori nel trapianto",
abstract = "Among the more recent immunosuppressive agents, Sirolimus and monoclonal antibodies directed against the IL-2 receptor are the most promising. Sirolimus inhibits the G1-S phase of the cell cycle, at a later stage than calcineurin inhibitors, which interfere with the G0-G1 phase. Clinical studies have demonstrated the efficacy of Sirolimus in reducing the risk of rejection when combined with CsA and steroids. Sirolimus also proved to be effective as an alternative to CsA. The monoclonal antibodies directed against the IL-2 receptor significantly reduce the risk of acute rejection without side-effects. Other immunosuppressive agents are still being assessed in phase I-H clinical studies. FTY 720 may induce selective apoptosis of lymphocytes reacting against the donor's alloantigens. Antisense oligonucleotides interfere with adhesion molecules, while the monoclonal antibodies CTLA4-Ig and 5C-8 interfere with the co-stimulatory signals between the antigen presenting cell and the lymphocyte. An ever increasing number of new immunosuppressive agents is becoming available. The difficult task of the clinician is to find the right equilibrium in dosing and associating these new drugs in order to maximize the therapeutic effect of immunosuppressive treatment.",
keywords = "Anti-IL-2 antibodies, Antisense oligonucleotides, Clinical trials, CTLA 4-Ig, FTY 720, Gusperimus, RAD, Renal transplantation, Sirolimus",
author = "C. Ponticelli and G. Montagnino",
year = "1999",
language = "Italian",
volume = "16",
pages = "180--185",
journal = "Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia",
issn = "0393-5590",
publisher = "Wichtig Publishing Srl",
number = "2",

}

TY - JOUR

T1 - Nuovi agenti immunosoppressori nel trapianto

AU - Ponticelli, C.

AU - Montagnino, G.

PY - 1999

Y1 - 1999

N2 - Among the more recent immunosuppressive agents, Sirolimus and monoclonal antibodies directed against the IL-2 receptor are the most promising. Sirolimus inhibits the G1-S phase of the cell cycle, at a later stage than calcineurin inhibitors, which interfere with the G0-G1 phase. Clinical studies have demonstrated the efficacy of Sirolimus in reducing the risk of rejection when combined with CsA and steroids. Sirolimus also proved to be effective as an alternative to CsA. The monoclonal antibodies directed against the IL-2 receptor significantly reduce the risk of acute rejection without side-effects. Other immunosuppressive agents are still being assessed in phase I-H clinical studies. FTY 720 may induce selective apoptosis of lymphocytes reacting against the donor's alloantigens. Antisense oligonucleotides interfere with adhesion molecules, while the monoclonal antibodies CTLA4-Ig and 5C-8 interfere with the co-stimulatory signals between the antigen presenting cell and the lymphocyte. An ever increasing number of new immunosuppressive agents is becoming available. The difficult task of the clinician is to find the right equilibrium in dosing and associating these new drugs in order to maximize the therapeutic effect of immunosuppressive treatment.

AB - Among the more recent immunosuppressive agents, Sirolimus and monoclonal antibodies directed against the IL-2 receptor are the most promising. Sirolimus inhibits the G1-S phase of the cell cycle, at a later stage than calcineurin inhibitors, which interfere with the G0-G1 phase. Clinical studies have demonstrated the efficacy of Sirolimus in reducing the risk of rejection when combined with CsA and steroids. Sirolimus also proved to be effective as an alternative to CsA. The monoclonal antibodies directed against the IL-2 receptor significantly reduce the risk of acute rejection without side-effects. Other immunosuppressive agents are still being assessed in phase I-H clinical studies. FTY 720 may induce selective apoptosis of lymphocytes reacting against the donor's alloantigens. Antisense oligonucleotides interfere with adhesion molecules, while the monoclonal antibodies CTLA4-Ig and 5C-8 interfere with the co-stimulatory signals between the antigen presenting cell and the lymphocyte. An ever increasing number of new immunosuppressive agents is becoming available. The difficult task of the clinician is to find the right equilibrium in dosing and associating these new drugs in order to maximize the therapeutic effect of immunosuppressive treatment.

KW - Anti-IL-2 antibodies

KW - Antisense oligonucleotides

KW - Clinical trials

KW - CTLA 4-Ig

KW - FTY 720

KW - Gusperimus

KW - RAD

KW - Renal transplantation

KW - Sirolimus

UR - http://www.scopus.com/inward/record.url?scp=0032701841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032701841&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0032701841

VL - 16

SP - 180

EP - 185

JO - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia

JF - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia

SN - 0393-5590

IS - 2

ER -